Gonadotropin-Releasing Hormone (GnRH) Agonist Global Market Report 2025
상품코드:1825752
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
성선자극호르몬 방출 호르몬(GnRH) 작용제 시장 규모는 향후 몇 년 동안 안정적으로 성장할 것으로 예상됩니다. 2029년에는 CAGR 2.5%로 46억 1,000만 달러로 성장할 것입니다. 예측 기간 동안 성장의 배경에는 인지도 향상 및 조기 진단, 의료비 지출 증가, 불임 치료에서의 사용 증가, 맞춤형 의료에 대한 수요 증가, 연구 자금 및 보조금 증가 등이 있습니다. 예측 기간 동안 주요 동향으로는 약물전달 시스템의 발전, 종양학 및 생식 의학의 발전, 호르몬 치료 옵션에 대한 수요 증가, 연구 개발 증가, 장시간 지속형 제제의 부상 등이 있습니다.
향후 5년간 2.5%의 성장률 전망은 지난번 전망치보다 0.3% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 관세 부과는 스위스나 인도에서 수입되는 류프로리드 아세테이트와 고세렐린 임플란트에 대한 접근을 제한하고 불임 치료와 전립선암 치료를 저해할 수 있는 한편, 내분비계 약품의 비용을 증가시킬 수 있기 때문에 미국에게 큰 도전이 될 수 있습니다. 또한, 상호 관세와 무역 마찰 및 규제 강화로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.
호르몬 관련 질환의 유병률 증가는 향후 몇 년 동안 성선자극호르몬 방출 호르몬(GnRH) 작용제 시장의 성장을 견인할 것으로 예상됩니다. 호르몬 관련 질환은 호르몬의 생산과 조절을 담당하는 내분비계의 불균형이나 기능 장애로 인해 발생하는 질환입니다. 당뇨병, 갑상선기능항진증, 전립선암 등의 질환이 이에 해당합니다. 호르몬 관련 질환의 유병률 증가는 환경적 영향, 비만, 대사증후군, 유전, 고령화 등의 요인에 기인합니다. GnRH 작용제는 호르몬 수치 조절에 중요한 역할을 하며, 호르몬 균형 장애 및 호르몬 의존성 질환과 관련된 병태생리를 치료하기 위한 개별화된 접근법을 제공합니다. 예를 들어, 2023년 12월 호주 통계청은 2022년에는 인구 약 20명 중 1명, 즉 인구의 5.3%(약 130만 명)가 당뇨병을 앓고 있다고 보고했습니다. 성별 유병률은 남성 5.8%, 여성 4.9%로 남녀 모두 비슷하게 나타났습니다. 또한, 당뇨병은 호주에서 7번째 사망원인이며, 그 해 사망자 수는 6,050명이었습니다. 따라서 호르몬 관련 질환의 유병률 증가는 GnRH 작용제 시장의 성장에 박차를 가하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 성선자극호르몬 방출 호르몬(GnRH) 작용제 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 성선자극호르몬 방출 호르몬(GnRH) 작용제 시장 : 성장률 분석
세계의 성선자극호르몬 방출 호르몬(GnRH) 작용제 시장 실적 : 규모와 성장, 2019-2024
세계의 성선자극호르몬 방출 호르몬(GnRH) 작용제 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계의 성선자극호르몬 방출 호르몬(GnRH) 작용제 : 총 잠재 시장 규모(TAM)
제6장 시장 세분화
세계의 성선자극호르몬 방출 호르몬(GnRH) 작용제 시장 : 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
류프로레린
고세레린
타르치레린
히스테리 트레이닝 인
기타 유형
세계의 성선자극호르몬 방출 호르몬(GnRH) 작용제 시장 처방별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
주사제
임플란트
경구
코 스프레이
세계의 성선자극호르몬 방출 호르몬(GnRH) 작용제 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원 약국
소매 약국
온라인 약국
세계의 성선자극호르몬 방출 호르몬(GnRH) 작용제 시장 : 용도별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
전립선암
유방암
자궁내막증
자궁근종
이른 발차성 청소년기
불임 치료
기타 용도
세계의 성선자극호르몬 방출 호르몬(GnRH) 작용제 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원
전문 클리닉
외래 수술 센터(ASC)
기타 최종사용자
세계의 성선자극호르몬 방출 호르몬(GnRH) 작용제 시장 : 하위 세분화 류프로레린(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
주사용 류프로레린
이식형 류프로레린
세계의 성선자극호르몬 방출 호르몬(GnRH) 작용제 시장 : 하위 세분화 고세레린(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
고세레린 주사제
고세레린인프란트
세계의 성선자극호르몬 방출 호르몬(GnRH) 작용제 시장 : 하위 세분화 타르치레린(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
주사용 타르치레린
경구 타르치레린
세계의 성선자극호르몬 방출 호르몬(GnRH) 작용제 시장 : 하위 세분화 히스테리 트레이닝 인, 종류별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
히스테리 트레이닝 인 임플란트
히스테리 트레이닝 인 주사
세계의 성선자극호르몬 방출 호르몬(GnRH) 작용제 시장 : 하위 세분화 기타 유형(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
트리프트레린
브세레린
나파레린
제7장 지역별·국가별 분석
세계의 성선자극호르몬 방출 호르몬(GnRH) 작용제 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 성선자극호르몬 방출 호르몬(GnRH) 작용제 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
성선자극호르몬 방출 호르몬(GnRH) 작용제 시장 : 경쟁 구도
성선자극호르몬 방출 호르몬(GnRH) 작용제 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
Sandoz Group AG Overview, Products and Services, Strategy and Financial Analysis
Ipsen Pharma Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
Aurobindo Pharma Limited
Cipla Limited
Dr Reddy's Laboratories Ltd.
Intas Pharmaceuticals Ltd.
Ferring Pharmaceuticals
Amneal Pharmaceuticals Inc.
Endo International plc
Lupin Limited
Gland Pharma Limited
Glenmark Pharmaceuticals Ltd.
Zydus Lifesciences Limited
Bachem Holding AG
Tolmar Pharmaceuticals Inc.
Debiopharm Group
Sun Pharmaceutical Industries Ltd.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
성선자극호르몬 방출 호르몬(GnRH) 작용제 시장 2029 : 새로운 기회를 제공하는 국가
성선자극호르몬 방출 호르몬(GnRH) 작용제 시장 2029 : 새로운 기회를 제공하는 부문
성선자극호르몬 방출 호르몬(GnRH) 작용제 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
KSM
영문 목차
영문목차
Gonadotropin-releasing hormone (GnRH) agonists are synthetic drugs that mimic the action of natural GnRH, stimulating the pituitary gland to release follicle-stimulating hormone (FSH) and luteinizing hormone (LH). These agents are employed to manage hormonal imbalances by regulating hormone levels and are particularly valuable in fertility treatments, where they help control and prevent premature ovulation during procedures such as in vitro fertilization.
The main types of GnRH agonists include leuprorelin, goserelin, taltirelin, histrelin, and others. Leuprorelin, a synthetic hormone, is used to treat prostate cancer, endometriosis, and uterine fibroids by decreasing hormone production. It is administered via monthly or quarterly injections and comes in various formulations, such as injectables, implants, oral tablets, and nasal sprays. Distribution channels for these medications include hospital pharmacies, retail pharmacies, and online pharmacies. Applications of leuprorelin encompass prostate cancer, breast cancer, endometriosis, uterine fibroids, precocious puberty, and fertility treatments, with end users including hospitals, specialty clinics, ambulatory surgical centers (ASCs), and other medical facilities.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The gonadotropin-releasing hormone (GnRH) agonists market research report is one of a series of new reports from The Business Research Company that provides gonadotropin-releasing hormone (GnRH) agonists market statistics, including the gonadotropin-releasing hormone (GnRH) agonists industry global market size, regional shares, competitors with the gonadotropin-releasing hormone (GnRH) agonists market share, detailed gonadotropin-releasing hormone (GnRH) agonists market segments, market trends, and opportunities, and any further data you may need to thrive in the gonadotropin-releasing hormone (GnRH) agonists industry. These gonadotropin-releasing hormone (GnRH) agonists market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The gonadotropin-releasing hormone (gnrh) agonist market size has grown steadily in recent years. It will grow from $4.1 billion in 2024 to $4.19 billion in 2025 at a compound annual growth rate (CAGR) of 2.1%. The growth in the historic period can be attributed to rising awareness and diagnosis of hormonal disorders, increasing prevalence of hormone-related diseases, increasing prevalence of prostate cancer, growing awareness about hormone therapy, increase demand for long-term safety and efficacy.
The gonadotropin-releasing hormone (gnrh) agonist market size is expected to see steady growth in the next few years. It will grow to $4.61 billion in 2029 at a compound annual growth rate (CAGR) of 2.5%. The growth in the forecast period can be attributed to rising awareness and early diagnosis, rising healthcare expenditure, increasing use in fertility treatments, rising demand for personalized medicine, and increasing research funding and grants. Major trends in the forecast period include advancements in drug delivery systems, advancements in oncology and reproductive medicine, growing demand for hormone therapy options, increasing research and development, and rise of long-acting formulations.
The forecast of 2.5% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for the U.S. by restricting access to leuprolide acetate and goserelin implants imported from Switzerland and India, potentially compromising fertility treatments and prostate cancer care while increasing endocrinology medication costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The rising prevalence of hormone-related diseases is expected to drive the growth of the gonadotropin-releasing hormone (GnRH) agonist market in the coming years. Hormone-related disorders are conditions caused by imbalances or dysfunctions in the endocrine system, which is responsible for producing and regulating hormones. These include diseases such as diabetes, hyperthyroidism, and prostate cancer. The increasing incidence of hormone-related diseases can be attributed to factors like environmental influences, obesity, metabolic syndrome, genetics, and the aging population. GnRH agonists play a crucial role in managing hormone levels and offer a personalized approach to treating conditions linked to hormonal imbalances and hormone-dependent diseases. For example, in December 2023, the Australian Bureau of Statistics reported that in 2022, about one in twenty people, or 5.3% of the population (approximately 1.3 million individuals), were living with diabetes. The prevalence was similar across genders, with 5.8% of males and 4.9% of females affected. Furthermore, diabetes was the seventh leading cause of death in Australia, contributing to 6,050 fatalities that year. Therefore, the increasing prevalence of hormone-related diseases is fueling the growth of the GnRH agonist market.
Companies in the GnRH agonist market are focusing on developing advanced androgen deprivation therapy (ADT) drugs to improve treatment efficacy and precision for hormone-sensitive cancers. ADT drugs, including GnRH analogs, work by reducing or eliminating androgen levels, thereby slowing or stopping the growth of hormone-sensitive cancers. For example, in January 2024, Zydus Lifesciences Limited, an India-based pharmaceutical company, introduced Relugolix under the brand name Rexigo. This is India's first and only once-daily oral therapy for testosterone suppression in advanced prostate cancer, eliminating the need for injectable treatments. Relugolix, a globally recognized active ingredient, provides rapid testosterone suppression. Rexigo is 50% more affordable than existing injectable treatments for advanced prostate cancer in India, marking a significant advancement in prostate cancer care by offering a safe, effective, and convenient treatment option for patients and healthcare providers.
In February 2022, Debiopharm, a Switzerland-based manufacturer of GnRH agonists, partnered with Aspen Holdings to launch Trelstar in South Africa. This collaboration aims to introduce Trelstar as a treatment for locally advanced and metastatic hormone-dependent prostate cancer. The partnership is set to deliver a high-quality oncology product, significantly enhancing prostate cancer treatment in the region and improving the overall treatment landscape for affected patients. Aspen Holdings, based in South Africa, provides specialty and generic pharmaceuticals.
Major companies operating in the gonadotropin-releasing hormone (GnRH) agonist market are Pfizer Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Sandoz Group AG, Ipsen Pharma, Aurobindo Pharma Limited, Cipla Limited, Dr Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., Ferring Pharmaceuticals, Amneal Pharmaceuticals Inc., Endo International plc, Lupin Limited, Gland Pharma Limited, Glenmark Pharmaceuticals Ltd., Zydus Lifesciences Limited, Bachem Holding AG, Tolmar Pharmaceuticals Inc., Debiopharm Group, Sun Pharmaceutical Industries Ltd.
North America was the largest region in the gonadotropin-releasing hormone (GnRH) agonist market in 2024. The regions covered in the gonadotropin-releasing hormone (GnRH) agonist market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the gonadotropin-releasing hormone (GnRH) agonist market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The gonadotropin-releasing hormone (GnRH) agonists market consists of sales of triptorelin, buserelin, and nafarelin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Gonadotropin-Releasing Hormone (GnRH) Agonist Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on gonadotropin-releasing hormone (gnrh) agonist market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for gonadotropin-releasing hormone (gnrh) agonist ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The gonadotropin-releasing hormone (gnrh) agonist market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Leuprorelin; Goserelin; Taltirelin; Histrelin; Other Types
2) By Formulation: Injectable; Implants; Oral; Nasal Sprays
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
4) By Application: Prostate Cancer; Breast Cancer; Endometriosis; Uterine Fibroids; Precocious Puberty; Fertility Treatment; Other Applications
5) By End-User: Hospital; Specialty Clinics; Ambulatory Surgical Centers (ASCs); Other End-Users
Subsegments:
1) By Leuprorelin: Injectable Leuprorelin; Implantable Leuprorelin
2) By Goserelin: Goserelin Injection; Goserelin Implant
3) By Taltirelin: Injectable Taltirelin; Oral Taltirelin
4) By Histrelin: Histrelin Implant; Histrelin Injection
5) By Other Type: Triptorelin; Buserelin; Nafarelin
3. Gonadotropin-Releasing Hormone (GnRH) Agonist Market Trends And Strategies
4. Gonadotropin-Releasing Hormone (GnRH) Agonist Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Growth Analysis And Strategic Analysis Framework
5.1. Global Gonadotropin-Releasing Hormone (GnRH) Agonist PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market Growth Rate Analysis
5.4. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Total Addressable Market (TAM)
6.1. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Leuprorelin
Goserelin
Taltirelin
Histrelin
Other Types
6.2. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Injectable
Implants
Oral
Nasal Sprays
6.3. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.4. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Prostate Cancer
Breast Cancer
Endometriosis
Uterine Fibroids
Precocious Puberty
Fertility Treatment
Other Applications
6.5. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital
Specialty Clinics
Ambulatory Surgical Centers (ASCs)
Other End-Users
6.6. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Sub-Segmentation Of Leuprorelin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Injectable Leuprorelin
Implantable Leuprorelin
6.7. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Sub-Segmentation Of Goserelin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Goserelin Injection
Goserelin Implant
6.8. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Sub-Segmentation Of Taltirelin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Injectable Taltirelin
Oral Taltirelin
6.9. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Sub-Segmentation Of Histrelin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Histrelin Implant
Histrelin Injection
6.10. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Triptorelin
Buserelin
Nafarelin
7. Gonadotropin-Releasing Hormone (GnRH) Agonist Market Regional And Country Analysis
7.1. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Gonadotropin-Releasing Hormone (GnRH) Agonist Market
9.1. China Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
9.2. China Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Gonadotropin-Releasing Hormone (GnRH) Agonist Market
10.1. India Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Gonadotropin-Releasing Hormone (GnRH) Agonist Market
11.1. Japan Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
11.2. Japan Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Gonadotropin-Releasing Hormone (GnRH) Agonist Market
12.1. Australia Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Gonadotropin-Releasing Hormone (GnRH) Agonist Market
13.1. Indonesia Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Gonadotropin-Releasing Hormone (GnRH) Agonist Market
14.1. South Korea Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
14.2. South Korea Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Gonadotropin-Releasing Hormone (GnRH) Agonist Market
15.1. Western Europe Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
15.2. Western Europe Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Gonadotropin-Releasing Hormone (GnRH) Agonist Market
16.1. UK Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.1. Germany Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Gonadotropin-Releasing Hormone (GnRH) Agonist Market
18.1. France Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.1. Spain Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Gonadotropin-Releasing Hormone (GnRH) Agonist Market
21.1. Eastern Europe Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
21.2. Eastern Europe Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Gonadotropin-Releasing Hormone (GnRH) Agonist Market
22.1. Russia Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Gonadotropin-Releasing Hormone (GnRH) Agonist Market
23.1. North America Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
23.2. North America Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Gonadotropin-Releasing Hormone (GnRH) Agonist Market
24.1. USA Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
24.2. USA Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Gonadotropin-Releasing Hormone (GnRH) Agonist Market
26.1. South America Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
26.2. South America Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Gonadotropin-Releasing Hormone (GnRH) Agonist Market
27.1. Brazil Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Gonadotropin-Releasing Hormone (GnRH) Agonist Market
28.1. Middle East Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
28.2. Middle East Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Gonadotropin-Releasing Hormone (GnRH) Agonist Market
29.1. Africa Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
29.2. Africa Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Gonadotropin-Releasing Hormone (GnRH) Agonist Market Competitive Landscape And Company Profiles
